Nervous System Diseases

1,005 trials 421 recruiting

Filter these 1,005 trials by phase, country and sponsor.

Open in Search →

A two-part, open-label study to assess the pharmacokinetics, pharmacodynamics and safety of single doses of inhaled and intravenously admini… Ended

2022-503037-63-00 Phase I, Clinical trial in healthy males and females in 3 2023-08-17
A study of the safety of the new investigational drug CVN293 in healthy volunteers, and how CVN293 is taken up and processed by the human bo… Ended

2023-506114-49-00 Neurodegenerative disorders 1 2023-08-15
Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2) Ended

2022-502000-73-00 Focal Onset Seizures 5 2023-08-11
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB) Ended

2023-504373-20-00 Subjects aged ≥55 years with probable Dementia with Lew 4 2023-08-09
UNITAS Ended

2022-502483-21-00 Insomnia disorder 4 2023-07-28
A research study looking at the effect of semaglutide on the immune system and other biological processes in people with Alzheimer's disease Ended

2023-506825-13-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2023-07-25
A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Gl… Ended

2023-506863-32-00 Multiple Sclerosis (MS) 3 2023-07-25
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE study) Ended

2022-501783-18-00 Parkinson’s Disease 4 2023-07-21
SAD and MAD of VENT-02 in healthy volunteers Ended

2023-505546-26-00 Neuroinflammatory and neurodegenerative diseases 1 2023-07-21
Ecopipam Tablets to Study Tourette’s Disorder in Children, Adolescents and Adults (D1AMOND) Ended

2023-503494-38-00 Tourette’s Disorder 5 2023-07-20
A clinical study of MK-6552 in healthy adults (MK-6552-002) Ended

2023-504954-37-00 Narcolepsy 3 2023-07-07
Basimglurant in children, adolescents, and young adults with TSC Ended

2024-512611-53-00 Tuberous Sclerosis Complex 4 2023-06-30
Open-label study to assess safety and efficacy of rapamycin in drugresistant epilepsy associated with mTOR pathway pathologies Ended

2024-515950-25-00 epilepsy, mTORopathies, focal cortical dysplasia, LEATS 4 2023-06-27
Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP. Ended

2024-512646-42-00 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP 4 2023-06-27
A Study of Suvecaltamide in Adults with Moderate to Severe Residual Tremor in Parkinson's Disease Ended

2024-515177-94-00 Parkinson's Disease 4 2023-06-21
Single dose, open-label, laboratory blinded, randomised, 2-treatment, 2-period, 2-sequence, crossover bioequivalence study of test product P… Ended

2023-504132-18-00 N.A. (submitted trial is a bioequivalence study in heal 2 2023-06-19
A Phase 2, Single-Blind, Placebo-Controlled Trial to Evaluate the Photoparoxysmal Electroencephalogram Response, Safety, Tolerability, and P… Ended

2023-504803-10-00 IPS induced photoparoxysmal electroencephalogram respon 4 2023-06-15
Randomized, double-blind, placebo-controlled study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of pitolisant a… Ended

2023-503945-78-00 Narcolepsy with cataplexy 3 2023-06-13
Outcome measures in SMA patients treated with Risdiplam. Ended

2022-501760-17-00 Spinal Muscular Atrophy (SMA) 5 2023-06-13
A study in healthy male adult participants to assess how much test medicine (SAR443820) is taken up, broken down and removed by the body whe… Ended

2022-502534-23-00 amyotrophic lateral sclerosis (ALS) 9 2023-06-02
A randomized, double-blind, single-center, 2-period cross-over Phase I study to assess the tolerability, safety and pharmacokinetics of anti… Ended

2023-503971-45-00 Depression 3 2023-06-01
Single dose, open-label, laboratory blinded, randomised, 2-treatment, 2-period, 2-sequence, crossover bioequivalence study of test product P… Ended

2023-503345-59-00 Not applicable (submitted trial is a bioequivalence stu 2 2023-05-23
A Single-Ascending-Dose Study of MK-4318 in Healthy Participants Ended

2023-503360-16-00 Acute and chronic pain 1 2023-05-02
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease Ended

2023-506872-29-00 Alzheimer's Disease 4 2023-04-13